Identifying high-risk patients with lung disease related to rheumatoid arthritis
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease (MOUNTAIN)
This study is trying to find out which patients with lung disease related to rheumatoid arthritis are at the highest risk of their condition getting worse.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 450 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | University of Colorado, Denver Academic / other |
| Locations | 4 sites (San Francisco, California and 3 other locations) |
| Trial ID | NCT06397677 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD) who are at the highest risk for disease progression. The investigators will collect clinical, radiologic, and biological data, including blood samples and high-resolution CT scans, to analyze potential markers associated with disease progression. Participants will undergo assessments at baseline and follow-up visits every four months for two years, allowing for comprehensive monitoring of their condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a multidisciplinary diagnosis of RA-ILD based on established criteria.
Not a fit: Patients who have previously received medication treatment specifically for RA-ILD or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better identification of patients at risk for progressive lung disease, enabling earlier interventions.
How similar studies have performed: Other studies have shown promise in identifying biomarkers and imaging features associated with lung disease progression, suggesting this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Multidisciplinary diagnosis of RA-ILD based on the 2010 American College of Rheumatology criteria * 18 years of age or older Exclusion Criteria: * Prior medication treatment specifically for RA-ILD * Inability to give informed consent * Pregnant women
Where this trial is running
San Francisco, California and 3 other locations
- University of California San Francisco — San Francisco, California, United States (Recruiting)
- University of Colorado Denver — Aurora, Colorado, United States (Recruiting)
- University of Kansas — Kansas City, Kansas, United States (Recruiting)
- University of Michigan — Ann Arbor, Michigan, United States (Recruiting)
Study contacts
- Principal investigator: Joyce S Lee — University of Colorado, Denver
- Study coordinator: Haylie Lengel
- Email: haylie.lengel@cuanschutz.edu
- Phone: 970-376-8303
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.